cytovance biologics, inc.
a cdmo platform providing end-to-end services related to mammalian cell culture, microbials, cell and gene therapies, and mrna products.
cdmo services
hepalink operates its fast-growing cdmo business through two of its wholly-owned subsidiaries, namely cytovance and spl, to seize growth opportunities in the global biopharmaceutical industry while supporting the clinical development of the company’s innovative drugs.
spl acquisition corp.
a cdmo platform specializes in the development and manufacturing of naturally derived pharmaceuticals.
cytovance biologics, inc.
in 2015, hepalink completed its acquisition of cytovance biologics, a leading biotechnology company specializes in the development and manufacturing of large molecule biologics.
- -located in the state of oklahoma, united stated
- -over 300 employees
- -specializes in recombinant and naturally derived large molecules and gene therapy products
- -developed over 170 large molecule biologic products targeting 15 therapeutic areas
- -in 2020, began manufacturing key enzymes to support the mass production of mrna covid-19 vaccines
spl acquisition corp.
in 2014, hepalink completed its acquisition of spl, the largest manufacturer of heparin sodium apis in the u.s.
- -located in the state of wisconcin, united states
- -specializes in the cgmp production of biopharmaceutical products, and is one of the world’s largest suppliers of heparin sodium, pancreatin, and pancrelipase apis.
- -provides cdmo services in current good manufacturing practices (cgmp)-compliant manufacturing of heparin derivatives, natural products extraction, fermentation and purification.